VORONOI
LIVE

Serial Number

79456193

Owner

Voronoi, Inc.

Filing Date

Jun 25, 2026

Add to watchlist:

No watchlists yet
View on USPTO

VORONOI Trademark

Serial Number: 79456193

VORONOI is a trademark filed by Voronoi, Inc. on June 25, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Voronoi, Inc.

S-18th F, Bldg. 32 Songdogwahak-ro,

Entity Type: 03

Trademark Details

Filing Date

June 25, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations and compositions for the treatment and prevention of protein kinase-related diseases; pharmaceutical preparations for treating metabolic disorders; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceutical preparations for the treatment of cancer; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory diseases; chemical preparations for medical purposes, namely, for the treatment of cancer; enzymes for medical purposes; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating tumors; pharmaceutical preparations for the diagnosis of cancer; pharmaceutical preparations for neurodegenerative diseases; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of lung cancer; antidiabetic preparations

Medical diagnostic assays for analyzing proteins; database design and development; scientific research conducted using databases; research relating to molecular sciences; research and development services of new pharmaceutical products using molecular modelling; research laboratory analysis services in the field of molecular biology; development of computer software for big data processing; technical data analysis services in the field of biotechnology; development of pharmaceuticals for cell therapies; development, updating and maintenance of software and database systems; drug discovery services; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; technical consultancy in the field of development of computer software for analyzing medical and biotechnological data; providing personalized medical data interpretation services, namely, medical data analysis services; research services in the field of pharmaceutical preparations; consultancy in the field of testing, inspection, research of pharmaceutical products; providing information on the testing, inspection and research of pharmaceutical products; medical and pharmacological research services; development of computer hardware for artificial intelligence services; research and development of computer software platforms for artificial intelligence services; development of computer software for artificial intelligence services

Filing History

APPLICATION FILING RECEIPT MAILED
Aug 31, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 31, 2026 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 28, 2026 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 13, 2026 REPR